ArticleScientific reports2022
Genomic analysis and in vivo efficacy of Pediococcus acidilactici as a potential probiotic to prevent hyperglycemia, hypercholesterolemia and gastrointestinal infections.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Probiotics as an adjunct in the treatment of canine atopic dermatitis: a systematic review and meta-analysis of in vivo studies in dogs.The Journal of veterinary medical science · 2025Pooled it
- Lacticaseibacillus paracasei SX52-B Isolated from Centenarians' feces: Genomic Analysis and Hypoglycemic Activity Evaluation.Probiotics and antimicrobial proteins · 2026Article
- Heat-InactivatedInternational journal of molecular sciences · 2025Article
- Whole Genome Analysis ofAntibiotics (Basel, Switzerland) · 2025Article
- Genomic profiling of pediococcus acidilactici BCB1H and identification of its key features for Biotechnological innovation, food technology and medicine.Scientific reports · 2025Article
- Integrative genomic characterization of five Pediococcus acidilactici strains reveals differing probiotic safety profiles.PloS one · 2025Article
- Genomic Insights intoAntibiotics (Basel, Switzerland) · 2024Article
- Antimicrobial use and resistance in food animal production: food safety and associated concerns in Sub-Saharan Africa.International microbiology : the official journal of the Spanish Society for Microbiology · 2024Review
- Novel Wild-TypeMicroorganisms · 2024Article
- Characterization ofInternational journal of microbiology · 2024Article
- Whole-genome sequencing and genomic analysis of fourFrontiers in microbiology · 2024Article
- Glucose-lowering effects of a synbiotic combination containing Pediococcus acidilactici in C. elegans and mice.Diabetologia · 2023Article
- In Vivo Functional Properties of Dairy Bacteria.Microorganisms · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Lactic acid bacteria are the well acknowledged probiotics that can cure a variety of diseases. In this study, we observed the in vivo potentials of Pediococcus to treat hyperglycemia, hypercholesterolemia and gastrointestinal infections. A total of 77 Lactobacillus were isolated from the milk of 10 cows and 10 goats, four of those strains inhibited both carbohydrates-hydrolyzing enzymes, α-glucosidase, and α-amylase. They all showed antagonistic effects on pathogenic E. coli and S. Typhimurium which were confirmed by performing pathogen challenge test and visualizing on Electron microscopy. 16S rRNA gene sequence identified that all four strains belong to Pediococcus genus which were further distinguished as Pediococcus acidilactici by pheS gene sequence. Whole genome sequence analysis revealed their non-pathogenic properties for human and the presence of probiotic genes responsible for stress resistance, immunomodulation, adhesion, metal and drug resistance. In vivo trial with diabetes-induced mice ascertained that all Pediococcus acidilactici had significant potentials to reduce elevated glucose and low-density lipoprotein level in blood. Interestingly, two out of four strains were significantly more effective (p < 0.0001 each) than metformin in reducing the blood glucose level. This in vivo study demonstrated that Pediococcus acidilactici might be a promising probiotic to prevent hyperglycemia, hypercholesterolemia and gastrointestinal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.